- Home
- TSHA vs ENGN Comparison
TSHA vs ENGN Comparison
Compare TSHA & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- ENGN
- Stock Information
- Founded
- TSHA 2019
- ENGN 1999
- Country
- TSHA United States
- ENGN Canada
- Employees
- TSHA N/A
- ENGN N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- ENGN
- Sector
- TSHA Health Care
- ENGN
- Exchange
- TSHA Nasdaq
- ENGN Nasdaq
- Market Cap
- TSHA 334.1M
- ENGN 317.6M
- IPO Year
- TSHA 2020
- ENGN N/A
- Fundamental
- Price
- TSHA $1.61
- ENGN $6.29
- Analyst Decision
- TSHA Strong Buy
- ENGN Buy
- Analyst Count
- TSHA 8
- ENGN 10
- Target Price
- TSHA $6.63
- ENGN $26.40
- AVG Volume (30 Days)
- TSHA 2.1M
- ENGN 179.7K
- Earning Date
- TSHA 02-26-2025
- ENGN 03-10-2025
- Dividend Yield
- TSHA N/A
- ENGN N/A
- EPS Growth
- TSHA N/A
- ENGN N/A
- EPS
- TSHA N/A
- ENGN N/A
- Revenue
- TSHA $9,915,000.00
- ENGN N/A
- Revenue This Year
- TSHA N/A
- ENGN N/A
- Revenue Next Year
- TSHA N/A
- ENGN N/A
- P/E Ratio
- TSHA N/A
- ENGN N/A
- Revenue Growth
- TSHA N/A
- ENGN N/A
- 52 Week Low
- TSHA $1.19
- ENGN $4.42
- 52 Week High
- TSHA $4.32
- ENGN $18.40
- Technical
- Relative Strength Index (RSI)
- TSHA 46.14
- ENGN 44.90
- Support Level
- TSHA $1.46
- ENGN $5.51
- Resistance Level
- TSHA $1.76
- ENGN $7.00
- Average True Range (ATR)
- TSHA 0.15
- ENGN 0.74
- MACD
- TSHA 0.01
- ENGN -0.01
- Stochastic Oscillator
- TSHA 39.33
- ENGN 43.43
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.